Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000670242 | SCV000795073 | likely pathogenic | Bloom syndrome | 2017-10-26 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000670242 | SCV004210853 | likely pathogenic | Bloom syndrome | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000670242 | SCV004642567 | uncertain significance | Bloom syndrome | 2023-02-16 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Studies have shown that disruption of this splice site is associated with altered splicing resulting in multiple RNA products (Invitae). ClinVar contains an entry for this variant (Variation ID: 554578). Disruption of this splice site has been observed in individual(s) with breast cancer (PMID: 32029870). This sequence change affects an acceptor splice site in intron 6 of the BLM gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BLM are known to be pathogenic (PMID: 17407155). |
Gene |
RCV004588096 | SCV005079977 | likely pathogenic | not provided | 2023-06-09 | criteria provided, single submitter | clinical testing | Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Observed in an individual with breast cancer (Hata et al., 2020); This variant is associated with the following publications: (PMID: 32029870) |